Patients with metastatic renal cell carcinoma treated with cabozantinib in the Czech Republic: analysis of four cancer centers
Authors:
Open Access
- 1 March 2022
- journal article
- research article
- Published by Palacky University Olomouc in Biomedical Papers
- Vol. 166 (1) , 97-104
Abstract
The aim of this study was to retrospectively analyze treatment outcomes and tolerance in patients in whom cabozantinib was used after previous targeted therapy. Cabozantinib was administered in dose 60 mg/day, a subset of patients received initial dose of 40 mg/day. The treatment was administered until to progression or unacceptable toxicity. CT scans were assessed according to the RECIST 1.1 and toxicity of treatment was assessed based on the CTCAE (version 4). Kaplan-Meier analysis was used to calculate progression free survival (PFS) and overall survival (OS). We performed a multivariate analysis of risk factors for treatment outcomes (PFS, OS) by Cox regression analysis. All statistics were evaluated at the significance level alpha = 0.05. 54 patients with metastatic renal cell carcinoma (mRCC) were evaluated. Median PFS in all patients treated with cabozantinib was 9.3 months (95% CI 5.3 - 13.3). One-year survival was 85.2% (95% CI 72.9 - 93.4%). Treatment response was observed in 45.9% of cases, including one complete remission. Cox regression analysis demonstrated that presence of subsequent treatment was the only factor with a significant effect on OS (P=0.008). Adverse events occurred in 88.9% of patients, grade 3 - 4 in 46.3%. The analysis of our cohort of patients treated with cabozantinib in the second or higher lines of treatment showed that cabozantinib represents an effective and safe therapy and contributes to longer survival of our mRCC patients.Keywords
This publication has 29 references indexed in Scilit:
- Cabozantinib Inhibits Prostate Cancer Growth and Prevents Tumor-Induced Bone LesionsClinical Cancer Research, 2014
- Pazopanib versus Sunitinib in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2013
- Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one databaseMedical Oncology, 2012
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor GrowthMolecular Cancer Therapeutics, 2011
- Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinibAnnals of Oncology, 2010
- Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall SurvivalJournal of Clinical Oncology, 2010
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 2010
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2009
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation TrialJournal of Clinical Oncology, 2009
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2007